| Eagle Pharmaceuticals Announces Receipt of Delisting Notification from Nasdaq | 08/27 16:30 | globenewswire.com |
| Eagle Pharmaceuticals to Present Additional Data from Phase III Trial Demonstrating Sustained Response of Amisulpride for the Rescue Treatment of Postoperative Nausea and Vomiting (PONV) at the Upcoming ASPAN 2024 National Conference in Orlando, Florida | 04/15 07:00 | globenewswire.com |
| Eagle Pharmaceuticals Announces Receipt of Notification of Deficiency from Nasdaq Regarding Requirement to Timely File Annual Report on Form 10-K | 04/12 16:05 | globenewswire.com |
| Shareholders of Eagle Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before February 9, 2024 to Discuss Your Rights - EGRX | 02/09 12:15 | accesswire.com |
| EAGLE PHARMACEUTICALS SHAREHOLDER ACTION REMINDER: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Eagle Pharmaceuticals To Contact Him Directly To Discuss Their Options | 02/09 12:00 | prnewswire.com |
| Levi & Korsinsky Reminds Eagle Pharmaceuticals, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 9, 2024 - EGRX | 02/09 11:30 | accesswire.com |
| Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of February 9, 2024 in Eagle Pharmaceuticals, Inc. Lawsuit - EGRX | 02/09 07:30 | accesswire.com |
| Eagle Pharmaceuticals, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before February 9, 2024 to Discuss Your Rights - EGRX | 02/09 05:45 | prnewswire.com |